NeuroSense Therapeutics Ltd. (NRSN)

NASDAQ: NRSN · Real-Time Price · USD

2.340

-0.040 (-1.68%)

Jun 16, 2025, 11:32 AM - Market open

NeuroSense Therapeutics Employees

NeuroSense Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.

Employees

17

Change (1Y)

-1

Growth (1Y)

-5.56%

Revenue / Employee

n/a

Profits / Employee

-$600,588

Market Cap

56.13M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	17	-1	-5.56%
Dec 31, 2023	18	4	28.57%
Dec 31, 2022	14	3	27.27%
Dec 31, 2021	11	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

NRSN News

4 weeks ago - Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - Benzinga
5 weeks ago - NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - PRNewsWire
7 weeks ago - NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - PRNewsWire
2 months ago - NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PRNewsWire
2 months ago - NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - PRNewsWire
2 months ago - NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting - PRNewsWire
3 months ago - PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape - Business Wire
5 months ago - NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - PRNewsWire